1711P SARS-CoV-2 infection in prostate cancer patients: Data from a high-incidence area in Italy

Abstract

Background: Novel SARS-CoV-2 infection has been a severe health problem in Italy since the beginning of March 2020, with around 227,000 confirmed cases on May 18th, 2020. The north-western part of Tuscany has been one of the areas with the highest incidence (342/100,000 inhabitants) and the highest lethality rate (31,2/ 100,000 inhabitants). The lethality rate was higher in men than women (12.6% vs. 7.4%). People aged 70-79 represented half of this population and the deaths in this subgroup represented 15.9% of all SARS-CoV-2-related deaths. Cancer patients are known to be at higher risk of incidence and complications from SARS-CoV-2. We aimed at analyzing the incidence and the lethality of Sars-CoV-2 in our prostate cancer (PC) patients (pts), in whom hormonal therapy seems to be protective from the first evidences published in the literature. Methods:We reviewed all the clinical files of PC pts'visits performed from March 1st to April 30th, 2020 in the University Hospital of Pisa. We analyzed the demographic characteristics, the comorbidities, the type of hormonal therapy pts received, the incidence of SARS-CoV-2 and the related lethality rate.

Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review

“…A search of the PubMed and Scopus databases and the proceedings of ASCO, ESMO, AUA, and EAU meetings from 1 January 2020 to 1 September 2021 identified 14 studies reporting the outcomes of PC patients with SARS-CoV-2 infection: five were published in the form of full papers (Caffo et al, 2020a;Di Lorenzo et al, 2020;Jimenez-Alcaide et al, 2021;Klein et al, 2021;Montopoli et al, 2020), and the others as letters (5) (Caffo et al, 2020b;Dalla Volta et al, 2020;Koskinen et al, 2020;Kwon et al, 2021;Patel et al, 2020) or meeting abstracts (4) (Duarte et al, 2021;Patel et al, 2021;Sbrana et al, 2020;Tucker et al, 2021). The results are summarised in Table 1.…”

“…The severity of infection outcomes in ADT + patients was usually expressed in terms of mortality, which ranged from 5.3%-38.2% (Caffo et al, 2020a, b;Dalla Volta et al, 2020;Jimenez-Alcaide et al, 2021;Klein et al, 2021;Kwon et al, 2021;Tucker et al, 2021). Two studies reported a mortality rate of 0%, but they respectively evaluated only one and two ADT + patients with infection (Di Lorenzo et al, 2020;Sbrana et al, 2020). Two studies investigated infection severity in terms of mortality and intensive care unit (ICU) admissions and, in these cases, severe outcomes were recorded in respectively 16.6 % and 25 % of patients (Koskinen et al, 2020;Montopoli et al, 2020).…”

“…First of all, most of the studies evaluated PC patients identified from hospital records (Caffo et al, 2020a, b;Dalla Volta et al, 2020;Di Lorenzo et al, 2020;Jimenez-Alcaide et al, 2021;Koskinen et al, 2020;Patel et al, 2020;Sbrana et al, 2020): this has the advantage of allowing the full availability of clinical information concerning disease stage and PC treatments, but excludes patients who are not regularly followed up in a hospital setting and screened for SARS-CoV-2 infection. In other words, a significant proportion of PC patients with or without COVID-19 (generally not receiving ADT) may be missed, and this can bias the study results.…”